Optimal sampling strategies for Bayesian estimation of docetaxel (Taxotere) clearance

Clinical Cancer Research

Volumn 3, Issue 9, 1997, Pages 1535-1538

  Baille, Pascale ^a   Bruno, René ^a   Schellens, Jan H M ^b,d   Webster, Lorraine K ^c   Millward, Michael ^c   Verweij, Jaap ^b   Montay, Guy ^a  

^a Rhône Poulenc Rorer ^*  (France)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL;

ARTICLE; BAYES THEOREM; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; HUMAN; LUNG NON SMALL CELL CANCER; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; SAMPLING; SOLID TUMOR;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BAYES THEOREM; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; HUMANS; INFUSIONS, INTRAVENOUS; LIKELIHOOD FUNCTIONS; LUNG NEOPLASMS; METABOLIC CLEARANCE RATE; NEOPLASMS; PACLITAXEL; PROSPECTIVE STUDIES; SAMPLING STUDIES; SPECIMEN HANDLING; TAXOIDS;

EID: 0030847811     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bruno, R., and Sanderink, G. Pharmacokinetics and metabolism of Taxotere. Cancer Surv., 17: 305-313, 1993.
2. Cortes, J. E., and Pazdur, R. Docetaxel. J. Clin. Oncol., 13: 2643-2655, 1995.
3. Pronk, L. C., Stoter, G., and Verweij, J. Docetaxel (Taxotere®): single agent activity, development of combination treatments and reducing side-effects. Cancer Treat. Rev., 21: 463-478, 1995.
4. Bruno, R., Hille, D., Thomas, L., Riva, A., and Sheiner, L. B. Population pharmacokinetics/pharmacodynamics (PK/PD) of docetaxel (Taxotere®) in Phase II studies. Proc. Am. Soc. Clin. Oncol., 14: 457, 1995.
5. Bruno, R., Vivier, N., Vergniol, J. C., De Phillips, S. L., Montay, G., and Sheiner, L. B. A population pharmacokinetic model for docetaxel (Taxotere®): model building and validation. J. Pharmacokinet. Biopharm., 24: 153-172, 1996.
6. Thomson, A. H., and Whiting, B. Bayesian parameter estimation and population pharmacokinetics. Clin. Pharmacokinet., 22: 447-467, 1992.
7. Egorin, M. J. Therapeutic drug monitoring and dose optimisation in oncology. In: P. Workman (ed.), New Approaches in Cancer Pharmacology: Drug Design and Development, pp. 75-91. Berlin: Springer-Verlag, 1992.
8. Maitre, P. O., Bührer, M., Thomson, D., and Stanski, D. R. A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam. J. Pharmacokinet. Biopharm., 19: 377-384, 1991.
9. Mandema, J. W., Verotta, D., and Sheiner, L. B. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J. Pharmacokinet. Biopharm., 20: 511-528, 1992.
10. Bruno, R., Iliadis, M. C., Lacarelle, B., Cosson, V., Mandema, J. W., Le Roux, Y., Montay, G., Durand, A., Ballereau, M., Alasia, M., Albanese, J., François, G., Iliadis, A., and Frydman, A. Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic analysis: application to pefloxacine in intensive care unit patients. J. Pharmacokinet. Biopharm., 20: 653-669, 1992.
11. D'Argenio, D. Z. Optimal sampling times for pharmacokinetic experiments. J. Pharmacokinet. Biopharm., 9: 739-756, 1981.
12. Van Warmerdam, L. J. C., ten Bokkel Huinink, W. W., Maes, R. A. A., and Beijnen, J. H. Limited-sampling models for anticancer agents. J. Cancer Res. Clin. Oncol., 120: 427-433, 1994.
13. Jodrell, D. I., Murray, L. S., Hawtof, J., Graham, M. A., and Egorin, M. J. A comparison of methods for limited-sampling strategy design using data from a Phase I trial of the anthrapyrazole DuP-941. Cancer Chemother. Pharmacol., 37: 356-362, 1996.
14. Pronk, L. C., Schellens, J. H. M., Planting, A. S. T., van den Bent, M. J., van der Burg, M. E. L., de Boer-Dennert, M., Ma, J., Blanc, C., Harteveld, M., Bruno, R., Stoter, G., and Verweij, J. A phase I and pharmacologic study of Docetaxel and Cisplatin in patients with advanced solid tumors. J. Clin. Oncol., 15: 1071-1079, 1997.
15. Millward, M. J., Zalcberg, J., Bishop, J. F., Webster, L. K., Zimet, A., Rischin, D., Toner, G. C., Laird, J., Cosolo, W., Urch, M., Bruno, R., Loret, C., James, R., and Blanc, C. Phase I trial of Docetaxel and Cisplatin in previously untreated patients with advanced non-small cell lung cancer. J. Clin. Oncol., 15: 750-758, 1997.
16. Vergniol, J. C, Bruno, R., Montay, G., and Frydman, A. Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J. Chromatogr., 582: 273-278, 1992.
17. Iliadis, A., Brown, A. C., and Huggins, M. L. APIS: a software for model identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics. Comput. Methods Programs Biomed., 38: 227-239, 1992.
18. Beal, S. L., Boeckman, A. J., and Sheiner, L. B. NONMEM: User's Guide, Parts I-VI. University of California at San Francisco, San Francisco, 1988-1992.
19. Sheiner, L. B., and Beal, S. L. Some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharm., 9: 503-512, 1981.